Select your Market
Financial results of Q1 2024
Forecast for fiscal 2024
| Q1 2024 (in € billion) | Change (in %, compared to Q1 2023) | Organic change (in %, compared to Q1 2023) |
|---|---|---|---|
Group net sales | 5.1 | -3.3 | -1.2 |
EBITDA pre | 1.5 | ‑8.4 | ‑5.2 |
Life Science sales | 2.1 | -13.8 | -12.6 |
Healthcare sales | 2.0 | 7.5 | 10.1 |
Electronics sales | 0.9 | 3.1 | 6.3 |
We had a good start to the year and gained initial momentum in the first quarter of 2024, once again benefiting from our diversified business model. We expect acceleration in the second half of the year, especially in Life Science, and thus a gradual return to organic growth for the Group in fiscal 2024.
Detailed information about the development of our business in the first quarter of 2024.
Downloads for the Media
Additional Downloads
Press Releases
The positive development of Healthcare and Electronics largely compensated for the decline in Life Science.
2024/05/15
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
